Li Xianchi, Liu Min, Sun Rongrong, Zeng Yi, Chen Shuang, Zhang Peiying
Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China.
Department of Cardiology, Xuzhou Clinical School of Xuzhou Medical College, Xuzhou, Jiangsu 221009, P.R. China.
Exp Ther Med. 2016 Dec;12(6):3823-3829. doi: 10.3892/etm.2016.3877. Epub 2016 Nov 7.
Myocardial ischemia-reperfusion is the leading cause for the events of cardiovascular disease, and is considered as a major contributor to the morbidity and mortality associated with coronary occlusion. The myocardial damage caused by ischemia-reperfusion injury constitutes the primary pathological manifestation of coronary artery disease. It results from the interaction between the substances that accumulate during ischemia and those that are delivered on reperfusion. The level of this damage can range from a small insult resulting in limited myocardial damage to a large injury culminating in myocyte death. Importantly, major ischemia-reperfusion injury to the heart can result in permanent disability or death. Given the worldwide prevalence of coronary artery disease, developing a strategy to provide cardioprotection against ischemia-reperfusion-induced damage is of great importance. Currently, the treatment of reperfusion injury following ischemia is primarily supportive, since no specific target-oriented therapy has been validated thus far. Nevertheless, therapeutic approaches to protect against myocardial ischemia-reperfusion injury remain an active area of investigation given the detrimental effects of this phenomenon.
心肌缺血再灌注是心血管疾病事件的主要原因，被认为是与冠状动脉闭塞相关的发病率和死亡率的主要促成因素。缺血再灌注损伤引起的心肌损伤是冠状动脉疾病的主要病理表现。它是由缺血期间积累的物质与再灌注时输送的物质之间的相互作用导致的。这种损伤的程度范围从导致有限心肌损伤的小损伤到最终导致心肌细胞死亡的大损伤。重要的是，心脏的严重缺血再灌注损伤可导致永久性残疾或死亡。鉴于冠状动脉疾病在全球的患病率，制定一种针对缺血再灌注诱导损伤提供心脏保护的策略非常重要。目前，缺血后再灌注损伤的治疗主要是支持性的，因为迄今为止尚未验证任何特定的靶向治疗方法。然而，鉴于这种现象的有害影响，预防心肌缺血再灌注损伤的治疗方法仍然是一个活跃的研究领域。
